Vincerx Pharma, Inc.
Vincerx Pharma, Inc. (VINC): 1 pipeline candidate · ~3 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.1 months
D/E 1.27 · 0% dilution
Lead: Approved
1 candidate
N/A
N/A
A transparent, data-derived signal for Vincerx Pharma, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$68K
Cash
$4.5M
Quarterly Burn
$4.5M
Runway
3.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| lastac system | Approved |
Frequently asked questions
How many drug candidates are in Vincerx Pharma, Inc.'s pipeline?
Vincerx Pharma, Inc. (VINC) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Vincerx Pharma, Inc.'s lead drug candidate?
Vincerx Pharma, Inc.'s most advanced tracked candidate is lastac system (Approved) for Cardiovascular.
What is Vincerx Pharma, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Vincerx Pharma, Inc. has approximately 3.1 months of cash runway.
What is Vincerx Pharma, Inc.'s market capitalization?
Vincerx Pharma, Inc.'s market capitalization is approximately $68K.
Who is the CEO of Vincerx Pharma, Inc.?
Dr. Raquel E. Izumi Ph.D. is the chief executive officer of Vincerx Pharma, Inc. (VINC).
Get the full picture on Vincerx Pharma, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.